TEGAFUR
Adjuvant Chemotherapy
Peking University Cancer Hospital & InstituteSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Adjuvant Chemotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Peg-Rhg-Csf Shandong University | Phase 4 | BB |
Capecitabine Fudan University | Phase 3 | BB |
Eloxatin Fudan University | Phase 3 | BB |
OTERACIL Peking University Cancer Hospital & Institute | Phase 3 | B |
Nivolumab Fundación GECP | Phase 3 | B |
View all 21 →
Same molecule, other indications
TEGAFUR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →